

Tania Bubela

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2781279/publications.pdf>

Version: 2024-02-01

93
papers

2,094
citations

257101

24
h-index

264894

42
g-index

96
all docs

96
docs citations

96
times ranked

3160
citing authors

#	ARTICLE	IF	CITATIONS
1	CAPTURE ALS: the comprehensive analysis platform to understand, remedy and eliminate ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, , 1-7.	1.1	3
2	The Importance of and Challenges with Adopting Life-Cycle Regulation and Reimbursement in Canada. Healthcare Policy, 2022, 17, 81-90.	0.3	0
3	Covid-19 threat and coping: application of protection motivation theory to the pandemic experiences of people affected by amyotrophic lateral sclerosis. BMC Neurology, 2022, 22, 140.	0.8	3
4	Public Engagement. World Scientific Series in Global Healthcare Economics and Public Policy, 2022, , 337-367.	0.1	0
5	Let's do better: public representations of COVID-19 science. Facets, 2021, 6, 403-423.	1.1	25
6	Communication About End of Life for Patients Living With Amyotrophic Lateral Sclerosis: A Scoping Review of the Empirical Evidence. Frontiers in Neurology, 2021, 12, 683197.	1.1	4
7	Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness. Frontiers in Medicine, 2021, 8, 818647.	1.2	7
8	Application of protection motivation theory to clinical trial enrolment for pediatric chronic conditions. BMC Pediatrics, 2020, 20, 123.	0.7	10
9	Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment. BMC Public Health, 2020, 20, 89.	1.2	2
10	Open drug discovery of anti-virals critical for Canada's pandemic strategy. Facets, 2020, 5, 1019-1036.	1.1	2
11	Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol. F1000Research, 2020, 9, 485.	0.8	2
12	Canada's Assisted Human Reproduction Act: Pragmatic Reforms in Support of Research. Frontiers in Medicine, 2019, 6, 157.	1.2	7
13	Participant perspectives on a phase I/II ocular gene therapy trial (NCT02077361). Ophthalmic Genetics, 2019, 40, 276-281.	0.5	7
14	Medical Information Commons to Support Learning Healthcare Systems: Examples From Canada. Journal of Law, Medicine and Ethics, 2019, 47, 97-105.	0.4	6
15	Importance of Participant-Centricity and Trust for a Sustainable Medical Information Commons. Journal of Law, Medicine and Ethics, 2019, 47, 12-20.	0.4	20
16	Recommendations for Regulating the Environmental Risk of Shedding for Gene Therapy and Oncolytic Viruses in Canada. Frontiers in Medicine, 2019, 6, 58.	1.2	6
17	Monitoring progress toward United Nations commitments: characteristics of Canadian legislation to promote tobacco control, physical activity and healthy eating. A descriptive study. CMAJ Open, 2019, 7, E745-E753.	1.1	4
18	The Impact of Heterogeneity in a Global Knowledge Commons: Implications for Governance of the DNA Barcode Commons. International Journal of the Commons, 2019, 13, 909-930.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Governance of a global genetic resource commons for non-commercial research: A case-study of the DNA barcode commons. <i>International Journal of the Commons</i> , 2019, 13, 205.	0.6	6
20	Provenance and risk in transfer of biological materials. <i>PLoS Biology</i> , 2018, 16, e2006031.	2.6	7
21	Non-invasive Prenatal Testing and the Unveiling of an Impaired Translation Process. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2017, 39, 10-17.	0.3	19
22	The ethics of genome editing in the clinic: A dose of realism for healthcare leaders. <i>Healthcare Management Forum</i> , 2017, 30, 159-163.	0.6	2
23	Responsible Translation of Stem Cell Research: An Assessment of Clinical Trial Registration and Publications. <i>Stem Cell Reports</i> , 2017, 8, 1190-1201.	2.3	55
24	L'Éthique de la modification du génome en clinique : une dose de réalisme pour les leaders en santé. <i>Healthcare Management Forum</i> , 2017, 30, 164-169.	0.6	0
25	Automated content analysis as a tool for research and practice: a case illustration from the Prairie Creek and Nico environmental assessments in the Northwest Territories, Canada. <i>Impact Assessment and Project Appraisal</i> , 2017, 35, 139-147.	1.0	3
26	Opportunities and challenges for the cellular immunotherapy sector: a global landscape of clinical trials. <i>Regenerative Medicine</i> , 2017, 12, 623-636.	0.8	8
27	Non-invasive Prenatal Testing and the Unveiling of an Impaired Translation Process. <i>Obstetrical and Gynecological Survey</i> , 2017, 72, 270-272.	0.2	0
28	Experiences in Broker-Facilitated Participatory Cross-Cultural Research. <i>International Journal of Qualitative Methods</i> , The, 2017, 16, 160940691770688.	1.3	4
29	Creating a data resource: what will it take to build a medical information commons?. <i>Genome Medicine</i> , 2017, 9, 84.	3.6	36
30	Legal Issues in Public Health. , 2017, , 384-390.		0
31	Governance of Biomedical Research Commons to Advance Clinical Translation: Lessons from the Mouse Model Community. , 2017, , 222-258.		1
32	Reproducibility and Reuse of Adaptive Immune Receptor Repertoire Data. <i>Frontiers in Immunology</i> , 2017, 8, 1418.	2.2	102
33	Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic. <i>Genome Medicine</i> , 2017, 9, 85.	3.6	17
34	Paving the road to personalized medicine: recommendations on regulatory, intellectual property and reimbursement challenges. <i>Journal of Law and the Biosciences</i> , 2017, 4, 453-506.	0.8	30
35	More Haste, Less Speed: Could Public-Private Partnerships Advance Cellular Immunotherapies?. <i>Frontiers in Medicine</i> , 2017, 4, 134.	1.2	8
36	Cell therapy licensing: a web for the unwary in <i>Kimble v. Marvel Entertainment?</i> . <i>Regenerative Medicine</i> , 2016, 11, 125-127.	0.8	0

#	ARTICLE	IF	CITATIONS
37	DNA barcoding in the media: does coverage of cool science reflect its social context?. <i>Genome</i> , 2016, 59, 738-750.	0.9	9
38	The mouse that trolled (again). <i>Journal of Law and the Biosciences</i> , 2016, 3, 185-191.	0.8	1
39	Precision medicine: drowning in a regulatory soup?. <i>Journal of Law and the Biosciences</i> , 2016, 3, 281-303.	0.8	18
40	Stepping Into and Out of the Void: Funding Dynamics of Human Embryonic Stem Cell Research in California, Sweden, and South Korea. <i>Stem Cell Reviews and Reports</i> , 2016, 12, 8-14.	5.6	4
41	The mouse that trolled: the long and tortuous history of a gene mutation patent that became an expensive impediment to Alzheimer's research. <i>Journal of Law and the Biosciences</i> , 2015, 2, 213-262.	0.8	7
42	â€œIf they tell me to get it, Iâ€™ll get it. If they donâ€™t....â€• Immunization decision-making processes of immigrant mothers. <i>Canadian Journal of Public Health</i> , 2015, 106, e230-e235.	1.1	63
43	Current practices and reform proposals for the regulation of advanced medicinal products in Canada. <i>Regenerative Medicine</i> , 2015, 10, 647-663.	0.8	14
44	Keeping score, strengthening policy and fighting bad actors over access to research tools. <i>Nature Biotechnology</i> , 2015, 33, 143-147.	9.4	5
45	Use and Misuse of Material Transfer Agreements: Lessons in Proportionality from Research, Repositories, and Litigation. <i>PLoS Biology</i> , 2015, 13, e1002060.	2.6	29
46	Circumpolar stakeholder perspectives on Geographic Information Systems for communicating the health impacts of development. <i>Environmental Science and Policy</i> , 2015, 54, 176-184.	2.4	6
47	Communicating the Promise for Ocular Gene Therapies: Challenges and Recommendations. <i>American Journal of Ophthalmology</i> , 2015, 160, 408-415.e2.	1.7	18
48	Bringing regenerative medicines to the clinic: the future for regulation and reimbursement. <i>Regenerative Medicine</i> , 2015, 10, 897-911.	0.8	41
49	Drugs: Regulate 'home-brew' opiates. <i>Nature</i> , 2015, 521, 281-283.	13.7	31
50	â€œIs a cure in my sight?â€• Multi-stakeholder perspectives on phase I choroideremia gene transfer clinical trials. <i>Genetics in Medicine</i> , 2014, 16, 379-385.	1.1	22
51	Implementing Socially Responsible Licensing for Global Health: Beyond Neglected Diseases. <i>Science Translational Medicine</i> , 2014, 6, 260cm11.	5.8	13
52	Legal Agreements and the Governance of Research Commons: Lessons from Materials Sharing in Mouse Genomics. <i>OMICS A Journal of Integrative Biology</i> , 2014, 18, 254-273.	1.0	13
53	Ocular gene transfer in the spotlight: implications of newspaper content for clinical communications. <i>BMC Medical Ethics</i> , 2014, 15, 58.	1.0	7
54	The global landscape of stem cell clinical trials. <i>Regenerative Medicine</i> , 2014, 9, 27-39.	0.8	143

#	ARTICLE	IF	CITATIONS
55	Policies and Practices to Enhance Multi-sectorial Collaborations and Commercialization of Regenerative Medicine. , 2014, , 67-87.		3
56	Value-engineered translation: developing biotherapeutics that align with health-system needs. American Journal of Managed Care, 2014, 20, E3.	0.8	3
57	Patent landscaping for life sciences innovation: toward consistent and transparent practices. Nature Biotechnology, 2013, 31, 202-206.	9.4	42
58	Patents and Misplaced Angst: Lessons for Translational Stem Cell Research from Genomics. Cell Stem Cell, 2013, 12, 508-512.	5.2	11
59	<i>AMP</i> v. <i>Myriad</i> : A Surgical Strike on Blockbuster Business Models. Science Translational Medicine, 2013, 5, 192ed9.	5.8	11
60	Reflections on the Cost of "Low-Cost" Whole Genome Sequencing: Framing the Health Policy Debate. PLoS Biology, 2013, 11, e1001699.	2.6	67
61	Prospects for scaling—up supervised injection facilities in <sc>C</sc>anada: the role of evidence in legal and political decision—making. Addiction, 2013, 108, 468-476.	1.7	33
62	Value-Engineered Translation for Regenerative Medicine: Meeting the Needs of Health Systems. Stem Cells and Development, 2013, 22, 89-93.	1.1	15
63	Access and benefits sharing of genetic resources and associated traditional knowledge in northern Canada: understanding the legal environment and creating effective research agreements. International Journal of Circumpolar Health, 2013, 72, 21351.	0.5	18
64	When Pictures Waste a Thousand Words: Analysis of the 2009 H1N1 Pandemic on Television News. PLoS ONE, 2013, 8, e64070.	1.1	14
65	Molecular Typing Technology: a Legal Perspective. Public Health Ethics, 2012, 5, 317-320.	0.4	4
66	Recalibrating Intellectual Property Rights to Enhance Translational Research Collaborations. Science Translational Medicine, 2012, 4, 122cm3.	5.8	32
67	Enabling advanced cell therapies (EnACT): invitation to an online forum on resolving barriers to clinical translation. Regenerative Medicine, 2012, 7, 735-740.	0.8	7
68	Is belief larger than fact: expectations, optimism and reality for translational stem cell research. BMC Medicine, 2012, 10, 133.	2.3	49
69	Introduction: Indigenous Rights and Traditional Knowledge. , 2012, , .		1
70	Synthetic biology confronts publics and policy makers: challenges for communication, regulation and commercialization. Trends in Biotechnology, 2012, 30, 132-137.	4.9	22
71	Aboriginal Rights and Traditional Ecological Knowledge in Northern Canada. , 2012, , .		0
72	Respecting and Aligning Knowledge Systems in Northern Canada: Beyond the International Polar Year. , 2012, , .		1

#	ARTICLE	IF	CITATIONS
73	Role and reality: technology transfer at Canadian universities. <i>Trends in Biotechnology</i> , 2010, 28, 447-451.	4.9	47
74	Commercialization and Collaboration: Competing Policies in Publicly Funded Stem Cell Research?. <i>Cell Stem Cell</i> , 2010, 7, 25-30.	5.2	27
75	Lost in translation: the Canadian access to medicines regime from transnational activism to domestic implementation. <i>Health Law Journal</i> , 2010, 18, 113-57.	0.2	2
76	International stem cell environments: a world of difference. <i>Nature Reports Stem Cells</i> , 2009, , .	0.1	7
77	Author name disambiguation for collaboration network analysis and visualization. <i>Proceedings of the American Society for Information Science and Technology</i> , 2009, 46, 1-20.	0.2	18
78	The Stem Cell Research Environment: A Patchwork of Patchworks. <i>Stem Cell Reviews and Reports</i> , 2009, 5, 82-88.	5.6	40
79	Post-publication sharing of data and tools. <i>Nature</i> , 2009, 461, 171-173.	13.7	142
80	Science communication reconsidered. <i>Nature Biotechnology</i> , 2009, 27, 514-518.	9.4	327
81	Framing Nutrigenomics for Individual and Public Health: Public Representations of an Emerging Field. , 2009, , 223-244.		0
82	Herbal remedy clinical trials in the media: a comparison with the coverage of conventional pharmaceuticals. <i>BMC Medicine</i> , 2008, 6, 35.	2.3	25
83	Why a Criminal Ban? Analyzing the Arguments Against Somatic Cell Nuclear Transfer in the Canadian Parliamentary Debate. <i>American Journal of Bioethics</i> , 2007, 7, 51-61.	0.5	31
84	Myriad and the mass media: the covering of a gene patent controversy. <i>Genetics in Medicine</i> , 2007, 9, 850-855.	1.1	50
85	Gene patentsâ€”more evidence needed, but policymakers must act. <i>Nature Biotechnology</i> , 2007, 25, 388-389.	9.4	6
86	Factors affecting the trappability of red foxes in Kosciusko National Park. <i>Wildlife Research</i> , 1998, 25, 199.	0.7	19
87	The social organisation and mating system of an Australian subalpine rodent, the broad-toothed rat, <i>Mastacomys fuscus</i> Thomas. <i>Wildlife Research</i> , 1993, 20, 405.	0.7	19
88	Home Range and Activity of the Broad-toothed Rat, <i>Mastacomys fuscus</i> , in Subalpine Heathland. <i>Wildlife Research</i> , 1991, 18, 39.	0.7	29
89	Diet of 2 Sympatric Australian Sub-Alpine Rodents, <i>Mastacomys-Fuscus</i> and <i>Rattus-Fuscipes</i> . <i>Wildlife Research</i> , 1990, 17, 479.	0.7	40
90	Intellectual Property and Biotechnology. , 0, , 1391-1432.		0

#	ARTICLE	IF	CITATIONS
91	Toward a New Era of Intellectual Property: From Confrontation to Negotiation - A Report by the International Expert Group on Biotechnology, Innovation and Intellectual Property. SSRN Electronic Journal, 0, , .	0.4	13
92	The New Age of the Nagoya Protocol. Nature Conservation, 0, 12, 43-56.	0.0	10
93	Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol. F1000Research, 0, 9, 485.	0.8	4